91九色视频

header-logo
GettyImages-609179959-hero
headshot

Deepak Kilari, MD

Associate Professor

view physician profile

Locations

  • Froedtert Hospital
  • Cancer Center - Froedtert Hospital

Specialties

  • Hematology
  • Medical Oncology

Languages

  • English, Telugu, Hindi

New & Established Patients Call

Education

  • MD - Doctor of Medicine

Biography

Deepak Kilari, MD, is an assistant professor in the division of hematology and oncology at the 91九色视频. Dr. Kilari moved back to the United States after finishing medical school at Andhra Medical College, India, to finish his internal medicine training at New York Methodist Hospital. In the course of his residency, he developed an interest in Oncology during his rotations at the Memorial Sloan Kettering Cancer Center, New York. Subsequently, he completed a fellowship in hematology and oncology at the University of Rochester, where he also served as a chief fellow. He received the American Society of Clinical Oncology (ASCO) Foundation Merit award in 2013. Dr. Kilari practices at Froedtert & the 91九色视频 Clinical Cancer Center and Moorland Reserve Clinic where he specializes in the management of patients with Genitourinary malignancies.

Research Interests

Dr. Kilari's clinical research interests focus on the development of better treatment options for patients with genitourinary malignancies. Dr. Kilari is Board Certified in Medical Oncology and Hematology.

Publications

  • (Jindal T, Jiang C, Alhalabi O, Nizam A, Nguyen C, Talukder R, Bakaloudi D, Davidsohn M, Freeman D, Glover M, Khaki AR, Evans S, Lemke E, Bose R, Sim W, Pywell C, Basu A, Kilari D, Barata PC, Bilen MA, Zakharia Y, Milowsky MI, Shah SA, Bellmunt J, Grivas P, Emamekhoo H, Davis NB, Gupta S, Hoimes C, Campbell MT, Alva A, Koshkin VS.) Eur Urol Oncol. 2025 Apr;8(2):258-262 PMID: 39709257 SCOPUS ID: 2-s2.0-105001942130 12/22/2024

  • (Basu A, Sidhom F, Hwang C, Ferguson J, Peyton C, Bae S, Kilari D, Desai A, Rais-Bahrami S.) J Natl Compr Canc Netw. 2025 Mar 28;23(3.5) PMID: 40154405 03/29/2025

  • (Li Q, Huang CC, Huang S, Tian Y, Huang J, Bitaraf A, Dong X, Nevalainen MT, Patel M, Wong J, Zhang J, Manley BJ, Park JY, Kohli M, Gore EM, Kilari D, Wang L.) Commun Med (Lond). 2025 Mar 04;5(1):61 PMID: 40038525 PMCID: PMC11880319 SCOPUS ID: 2-s2.0-86000110322 03/05/2025

  • (Raychaudhuri R, Tuchayi AM, Low SK, Arafa AT, Graham LS, Gulati R, Pritchard CC, Montgomery RB, Haffner MC, Nelson PS, Yu EY, Hawley JE, Cheng HH, Mo G, Chen DL, Antonarakis ES, Kilari D, Hope TA, Iravani A, Schweizer MT.) Eur Urol Oncol. 2025 Feb 06 PMID: 39920014 02/08/2025

  • (Bo AY, Cheng YC, George B, Kilari D, Thompson JR, Jorns JM.) Arch Pathol Lab Med. 2024 Dec 26 PMID: 39722594 12/26/2024

  • (Pierro MJ, Gallan A, Kilari D.) Transl Cancer Res. 2024 Nov 30;13(11):6403-6412 PMID: 39697750 PMCID: PMC11651800 12/19/2024

  • (Powles T, Catto JWF, Galsky MD, Al-Ahmadie H, Meeks JJ, Nishiyama H, Vu TQ, Antonuzzo L, Wiechno P, Atduev V, Kann AG, Kim TH, Suárez C, Chang CH, Roghmann F, Özgüro臒lu M, Eigl BJ, Oliveira N, Buchler T, Gadot M, Zakharia Y, Armstrong J, Gupta A, Hois S, van der Heijden MS, NIAGARA Investigators.) N Engl J Med. 2024 Nov 14;391(19):1773-1786 PMID: 39282910 09/17/2024

  • (Patel MS, Almubarak M, Matta J, Ortiz-Sanchez C, Encarnacion J, Ruiz-Deya G, Dutil J, Dhillon J, Yamoah K, Berglund A, Park H, Kilari D, Balagurunathan Y, Wang L, Park JY.) medRxiv. 2024 Oct 27 PMID: 39502659 PMCID: PMC11537326 11/06/2024

  • (Obasi J, Sharma K, De Sarkar N, Antonarakis ES, Kilari D.) Clinical Genitourinary Cancer. December 2024;22(6) SCOPUS ID: 2-s2.0-85203009546 12/01/2024

  • (Pierro MJ, Gallan A, Kilari D.) Translational Cancer Research. 30 November 2024;13(11):6403-6412 SCOPUS ID: 2-s2.0-85211012802 11/30/2024

  • (Davis NB, Kilari D, Kessler ER, Smelser WW.) Front Oncol. 2024;14:1493854 PMID: 39391248 PMCID: PMC11464248 10/11/2024

  • (Thapa B, De Sarkar N, Giri S, Sharma K, Kim M, Kilari D.) Cancer Manag Res. 2024;16:1267-1283 PMID: 39308935 PMCID: PMC11416116 SCOPUS ID: 2-s2.0-85204934732 09/23/2024

Publications of from the

© 2025 91九色视频.  All rights reserved.  | Terms and Privacy | Web Accessibility Statement

Non-Discrimination Statement
The 91九色视频 (91九色视频) is committed to fostering a diverse community of outstanding faculty, staff, and students, as well as ensuring equal educational opportunity, employment, and access to services, programs, and activities, without regard to an individual's race, color, national origin, religion, age, disability, sex, gender identity/expression, sexual orientation, marital status, pregnancy, predisposing genetic characteristic, or military status. Employees, students, applicants or other members of the 91九色视频 community (including but not limited to vendors, visitors, and guests) may not be subjected to harassment that is prohibited by law or treated adversely or retaliated against based upon a protected characteristic. 91九色视频’s policy as well as federal and state laws and regulations prohibit unlawful discrimination and harassment.

Notice of Compliance with Laws and Commitment to Civil Rights
The 91九色视频 is committed to full compliance with all applicable federal, state, and local laws and regulations in the pursuit of our missions. Consistent with recent federal guidance, we affirm our commitment to individual merit, fairness, and equal treatment in all aspects of academic and institutional decision-making. As part of this commitment, we are actively reviewing our policies and materials to ensure they align with federal nondiscrimination obligations.